PHK
PDLI

Point72 Hong Kong’s PDL BioPharma, Inc. PDLI Stock Holding History

Point72 Hong Kong’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,257
Closed -$7K – 1555
2019
Q4 		$7K Buy
+2,257
New +$6.55K ﹤0.01% 1029

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Hong Kong's PDLI Position: Q1 2020 in Review

Point72 Hong Kong sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 2,257 shares — an estimated $7K sold.

Point72 Hong Kong first reported a position in PDLI in Q4 2019 and held it in 1 quarter. The position peaked at $7K in Q4 2019. 133 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

  • Point72 Hong Kong reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
  • Point72 Hong Kong sold 2,257 PDL BioPharma, Inc. shares in Q1 2020, an estimated $7K.
  • Point72 Hong Kong first reported a position in PDL BioPharma, Inc. in Q4 2019 and held it in 1 quarter.
  • Point72 Hong Kong's PDL BioPharma, Inc. position peaked at $7K in Q4 2019.
  • 133 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Point72 Hong Kong's 13F filing for Q1 2020, filed 15 May 2020.